<DOC>
	<DOCNO>NCT01289899</DOCNO>
	<brief_summary>The objective study determine safety tolerability determine Pharmacokinetic Pharmacodynamic ( PK/PD ) ascend multiple oral dose BR-A-657 healthy male subject .</brief_summary>
	<brief_title>Fimasartan ( BR-A-657 ) Multiple Oral Dose Healthy Subjects</brief_title>
	<detailed_description>BR-A-657 120 , 360 , placebo administer daily 7days 16 healthy male subject . Pharmacokinetic Pharmacodynamic ( PK/PD ) parameter monitor pre-specified time subject . PK parameter : Area Under Curve ( AUC ) , Cmax , half-life , etc . PD parameter : Aldosterone , Plasma renin activity , Angiotensin I , Angiotensin II Adverse event report .</detailed_description>
	<criteria>male 1855 year old BMI 1929kg/m2 subject good health subject write informed consent subject multiple drug allergy allergy ARB subject medication affect drug absorption elimination within 30days . subject orthostatic hypotension &gt; 20mmHg decrease sbp subject history neurologic , liver , renal , GI , CV , psychological major disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>BR-A-657</keyword>
	<keyword>Fimasartan</keyword>
	<keyword>multiple-dose</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>safety</keyword>
</DOC>